[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355292-105":59,"doc-detail-355292-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mutation-of-rearranged-during-transfection-ret-is-associated-with-enhanced-tumor-immunogenicity-and-favorable-outcomes-in-pan-cancer-immunotherapy","Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy","","The proto-oncogene rearranged during transfection (RET) mutation can affect tumor immunogenicity and immune regulation through multiple pathways. This work performs integrated bioinformatic and clinical analyses to assess RET mutation features and how they relate to outcomes in pan-cancer immune checkpoint blockade (ICB). A discovery cohort and an independent validation cohort evaluate prognostic and response value, including multi-omics characterization. Results link RET mutation with improved survival and response, plus altered mutational signatures and enriched immune infiltration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mutation-of-rearranged-during-transfection-ret-is-associated-with-enhanced-tumor-immunogenicity-and-favorable-outcomes-in-pan-cancer-immunotherapy/355292/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mutation-of-rearranged-during-transfection-ret-is-associated-with-enhanced-tumor-immunogenicity-and-favorable-outcomes-in-pan-cancer-immunotherapy/355292.png","ImageObject",300,407,{"name":92,"@type":93},"Ophelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study focus regarding RET mutation?","Question",{"text":112,"@type":113},"The study evaluates how RET mutation characteristics relate to tumor immunogenicity and outcomes under pan-cancer immune checkpoint blockade (ICB).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the prognostic and response effects of RET mutation assessed?",{"text":117,"@type":113},"The predictive significance was evaluated in a discovery cohort and verified in an independent cohort, using TCGA multi-omics data and immune mechanism analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes are associated with RET mutation in ICI-treated patients?",{"text":121,"@type":113},"RET mutation is associated with favorable overall survival and higher objective response rates, along with immune-related multi-omics findings such as enhanced immune cell infiltration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355292,1790246319,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","The Oncologist, 2026, 31, oyag049  \n[https://doi.org/10.1093/oncolo/oyag049](https://doi.org/10.1093/oncolo/oyag049)  \n[Published: 17 February 2026](Published: 17 February 2026)  \nOriginal Article  \nMutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy  \nJingshuang Cai, MD1,†, Zhiyang Huang, MD1,†, Yingying Li, MSc1, Jin Zhou, MD1, Yingzhi Xu, MD1, Mingzhen Cai, MD1, Hong Zhao, MD, PhD2,*, Bin Zhao*,1,  \n1The Central Laboratory, Quanzhou First Hospital Affiliated to Fujian Medical University, 1028 Anji South Road, Quanzhou, Fujian, 362000, China 2The Cancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, 52 Meihua East Road, Zhuhai, Guangdong, 519000, China  \n*Corresponding authors: Hong Zhao, MD, PhD, The Cancer Center, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai 519000, China.  \n[E-mail:](E-mail: doctorhongzhao@163.com)[ doctorhongzhao@163.com](E-mail: doctorhongzhao@163.com); Bin Zhao, PhD, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou 362000, China.  \nE-mail: [doctorbinzhao@126.com](doctorbinzhao@126.com).  \n†Jiangshuang Cai and Zhiyang Huang contributed equally to this work, and should be considered as co-first authors.  \nAbstract  \nBackground: The proto-oncogene rearranged during transfection (RET) mutation can influence tumor immunogenicity and regulate immune responses through multiple pathways. Herein, we performed an in-depth bioinformatic and clinical analysis to systematically evaluate the attributes of RET mutation and their interconnections with outcomes in pan-cancer immune checkpoint blockade (ICB) therapeutic interventions.  \nMethods: The predictive significance of RET mutation was evaluated in a discovery cohort comprising 1406 patients with 6 tumor types, and the findings were verified in an independent cohort of 1524 individuals representing 9 tumor types. Utilizing The Cancer Genome Atlas (TCGA), we retrieved multi-omics data and further investigated both intrinsic and extrinsic immune response mechanisms behind the RET mutation.  \nResults: Among 2930 immune checkpoint inhibitor (ICI)-treated patients with 11 tumor types, the presence of RET mutation showed a significant association with favorable overall survival (HR, 0.60; 95% CI, 0.48-0.75; P\u003C .001) and objective response rate (44.9% vs. 25.7%; P\u003C .001). Furthermore, the frequencies of 6 mutational signatures related to immunotherapy outcomes, changed significantly in RET-mutant tumors. Additional multi-omics analysis on intrinsic and extrinsic immune landscapes elucidated that the RET mutation could enrich immune cell infiltration besides improving tumor immunogenicity, alongside immune responses.  \nConclusions: Rearranged during transfection mutation may enhance anti-tumor immunity and function as an independent biomarker for promising outcomes across multiple cancer types treated with ICB. These findings have the potential to inform clinical decision-making, guide personalized immunotherapy strategies, and contribute to the advancement of precision oncology.  \nKeywords RET mutation, cancer, biomarker, immune checkpoint blockade  \nImplications for Practice  \nRearranged during transfection-mutant tumors may be characterized as immunologically “hot” tumors, exhibiting enhanced immune activity and correlating with enhanced clinical outcomes in patients who received immunotherapy.  \nIntroduction  \nImmune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 have demonstrated significant clinical benefits and are  \nnow established as standard therapies in various malignancies.1,2 Despite the regulatory approval of several biomarkers, such as PD-L1 level, tumor mutation burden (TMB), along with microsatellite instability-high/deficient DNA mismatch repair, for the  \nReceived: March 20, 2025. Accepted: February 12, 2026  \n© The Author(s) 2026. Published by Oxford University Press.  \nThis is an ","cbCaij3lP69p8Dhb","https://ap.wps.com/l/cbCaij3lP69p8Dhb","pdf",2331329,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Implications for Practice\n# Introduction","[{\"question\":\"What is the study focus regarding RET mutation?\",\"answer\":\"The study evaluates how RET mutation characteristics relate to tumor immunogenicity and outcomes under pan-cancer immune checkpoint blockade (ICB).\"},{\"question\":\"How were the prognostic and response effects of RET mutation assessed?\",\"answer\":\"The predictive significance was evaluated in a discovery cohort and verified in an independent cohort, using TCGA multi-omics data and immune mechanism analyses.\"},{\"question\":\"What outcomes are associated with RET mutation in ICI-treated patients?\",\"answer\":\"RET mutation is associated with favorable overall survival and higher objective response rates, along with immune-related multi-omics findings such as enhanced immune cell infiltration.\"}]","Mutation of rearranged during transfection (RET) is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy | PDF",1790117414,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/328eb1492ec2b4a4bd2b199eb47ed2a2.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c26bbce1c9e42d2c89492535a0d15483.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f620e13343fc1cf505fc08208c8b2071.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8864440c2baa6d2f302d351ba3a5317.webp",980,1287]